HERCULES, Calif.--(BUSINESS WIRE)--
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the iQ-Check Prep Automation System from the United States Department of Agriculture’s Food Safety and Inspection Service (USDA FSIS).
The contract includes real-time PCR-based tests for pathogens that include Salmonella spp., Listeria monocytogenes, Campylobacter, Escherichia coli O157:H7, and Shiga toxin producing E. coli (STEC) that may be found in raw meat and poultry, ready to eat meat and poultry, processed egg products, and other food products and environmental samples. Bio-Rad’s iQ-Check real-time PCR test kits were selected based on their proven real-time PCR technology that uses highly specific patented DNA probes to detect pathogenic bacteria in a sample. USDA FSIS will also incorporate Bio-Rad’s iQ-Check Prep automation system for high throughput sample processing and elevated traceability.
“We are pleased to partner with the USDA to help protect the food supply,†said Annette Tumolo, Bio-Rad President, Life Science Group. “This is an exciting development for Bio-Rad, reflecting our strong performance in the area of rapid food pathogen testing solutions.â€
The iQ-Check kits for pathogen detection are routinely used in food safety programs worldwide, and are recognized by several renowned international validation organizations. For more information on Bio-Rad’s complete range of iQ-Check real-time PCR test kits, please visit www.bio-rad.com/iqcheck.
iQ-Check and Bio-Rad are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “willâ€, “believe,†“expect,†“anticipate,†“may,†“plan,†“intend,†“estimate,†“offers,†or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors†and “Management’s Discussion and Analysis of Financial Condition and Results of Operation†in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181113005242/en/